Pediapharm Inc. is a listed company. Its directors and officers file their transactions with SEDI. Nothing new has been filed by managers of Pediapharm Inc. in twelve months, the latest record being from 26 October 2018.
Over the whole record (from 2016), the tally stands at 20 purchases and 54 sales.
These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
25 of 99 declarations
Pediapharm Inc. is a Canadian company focused on the development and commercialization of medications for children. It is listed on the Toronto Stock Exchange under the symbol XTSE.